Risk Based Validation and Supplier Assessment
Risk-Based Approach to AI Validation
Organisations must apply risk-based thinking when validating artificial intelligence systems within pharmaceutical manufacturing and quality assurance processes. This approach requires identifying potential failure modes and their impact on product quality, patient safety, and regulatory compliance. The validation strategy should focus resources on areas where AI systems could cause significant harm or deviation from intended performance.
Consider a machine learning algorithm used to predict equipment maintenance schedules. A risk assessment identifies that incorrect predictions could lead to unplanned downtime, product contamination, or failure to meet regulatory deadlines. The validation approach must therefore include extensive testing of the algorithm’s predictive accuracy using historical data, validation against known maintenance events, and stress testing under various operational conditions.
The risk-based approach ensures that validation efforts concentrate on these high-impact scenarios rather than conducting identical testing across all system components.
ISO 13485 clause 7.4 addresses risk-based validation activities. The validation plan should document risk categories, including potential data integrity issues, algorithm bias, or computational errors. For example, an AI system predicting clinical trial outcomes must undergo validation that addresses data quality issues, algorithmic fairness, and computational reproducibility.
The risk assessment process identifies which validation activities require the most rigorous testing and documentation.
Supplier Assessment Framework
Organisations must evaluate AI suppliers through structured assessment processes that align with their own quality management systems. The supplier assessment framework should examine technical capabilities, data handling practices, regulatory compliance history, and organisational maturity. This evaluation helps identify potential risks associated with third-party AI solutions before implementation.
A pharmaceutical company considering an AI-based quality control system must assess whether the supplier maintains appropriate data security measures, follows established software development practices, and provides adequate documentation for regulatory submissions. The assessment process includes reviewing supplier quality management systems, examining their track record with similar clients, and verifying their ability to provide ongoing support and updates.
The supplier must demonstrate compliance with relevant regulatory requirements including data protection legislation and good manufacturing practice standards.
- Supplier technical capabilities including algorithm development, data processing, and computational infrastructure
- Data handling practices including storage, access controls, and data retention policies
- Regulatory compliance history and documentation support for audit readiness
- Organisational maturity regarding quality management, change control, and incident response
ISO 13485 clause 8.2 specifies supplier evaluation requirements. The assessment must verify that suppliers can consistently deliver products meeting specified requirements. For AI systems, this includes confirming that algorithms perform as claimed, data inputs are properly validated, and outputs meet clinical or manufacturing requirements.
The supplier assessment process should include on-site visits, reference checks, and technical demonstrations of the AI system in operation.
Implementation and Ongoing Monitoring
Effective risk-based validation and supplier assessment require continuous monitoring and periodic reassessment. Organisations must establish processes for tracking AI system performance, identifying potential issues, and implementing corrective actions. This ongoing approach ensures that validation remains relevant as systems evolve and operational conditions change.
A pharmaceutical manufacturer using AI for batch release decisions must monitor system performance through regular validation reviews, data quality assessments, and clinical validation studies. The organisation should track whether AI predictions align with actual outcomes, identify any drift in algorithm performance, and maintain records of any modifications or updates to the AI system.
Regular supplier performance reviews ensure that third-party providers continue meeting agreed requirements and maintain appropriate quality standards.
ISO 13485 clause 9.1 addresses monitoring and measurement activities. The validation programme must include metrics for tracking AI system effectiveness, such as prediction accuracy rates, false positive/negative ratios, and computational efficiency. These metrics provide objective measures of system performance and support ongoing validation activities.
The supplier assessment process should include regular reviews of supplier performance, including incident reporting, change management effectiveness, and support response times. These activities ensure that AI systems continue to meet organisational requirements throughout their operational lifecycle.
Organisations should maintain detailed records of validation activities, supplier assessments, and ongoing monitoring results. These records support regulatory submissions, internal audits, and continuous improvement efforts. The risk-based approach ensures that validation resources focus on areas of highest potential impact, while supplier assessment activities identify and mitigate risks associated with third-party AI solutions.